Levonorgestrel intrauterine system for the treatment of intermenstrual spotting in patients with previous cesarean delivery scar defect

• Published in: The journal of obstetrics and gynaecology research Vol. 48; no. 1; pp. 155 - 160
• Main Authors: Ou, Yu‐Che, Chen, Ying‐Yi, Lan, Kuo‐Chung, Tsai, Ching‐Chang, Chu, Li‐Ching, Cheng, Ling‐Yun
• Format: Journal Article
• Language: English
• Published: Kyoto, Japan John Wiley & Sons Australia, Ltd 01.01.2022; Wiley Subscription Services, Inc
• Subjects: Bleeding; Cesarean section; Cicatrix; Female; Humans; Inflammatory diseases; intermenstrual bleeding; intrauterine device; Intrauterine devices; Intrauterine Devices, Medicated - adverse effects; IUD; Levonorgestrel - adverse effects; LNG‐IUS; Medical records; Menstruation; Metrorrhagia; Patients; Pregnancy; previous cesarean delivery scar defect; Retrospective Studies; Uterus; cesarean section; intermenstrual bleeding; intrauterine device; previous cesarean delivery scar defect; LNG-IUS
• ISSN: 1341-8076; 1447-0756; 1447-0756
• DOI: 10.1111/jog.15062

Aim To evaluate the efficacy of levonorgestrel 52 mg intrauterine system for intermenstrual bleeding in patients with previous cesarean delivery scar defects (PCDSs). Methods The medical records of 28 consecutive patients with previous cesarean delivery scar defect and intermenstrual bleeding who had undergone conservative treatment with levonorgestrel 52 mg intrauterine system were reviewed. The efficacy of treatment and frequency of adverse events were measured retrospectively. Results After 1 year of treatment, 22 patients (78.6%) reported an improvement in symptoms. The mean duration of menstruation were 18 and 5 days before and after treatment, respectively. No uterine perforations or pelvic inflammatory diseases occurred during or after the insertion procedures. Eighteen (64.3%) patients did not experience any adverse events, and the patients with adverse events reported that they could be managed by adjusting their medications or observation. Conclusion Levonorgestrel intrauterine system may have a role in the safe and effective management of intermenstrual spotting in patients with PCDSs.